Relmada Therapeutics (RLMD) Misses Q1 EPS by 21c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.58), $0.21 worse than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- X Financial (XYF) Tops Q2 EPS by 438c
- H.B. Fuller board rejects Ancora's $1.1B-$1.2B BAS unit bid
- Laser Photonics unit wins $1.05M pharma tablet drilling order
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
